Related references
Note: Only part of the references are listed.Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria
Lakshminarayan R. Ranganath et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2020)
Pigmentation Chemistry and Radical-Based Collagen Degradation in Alkaptonuria and Osteoarthritic Cartilage
Wing Ying Chow et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial
Lakshminarayan R Ranganath et al.
Lancet Diabetes & Endocrinology (2020)
A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to Alkaptonuria
Brendan P. Norman et al.
CLINICAL CHEMISTRY (2019)
Assessing the effect of nitisinone induced hypertyrosinaemia on monoamine neurotransmitters in brain tissue from a murine model of alkaptonuria using mass spectrometry imaging
Andrew S. Davison et al.
METABOLOMICS (2019)
Ochronotic pigmentation is caused by homogentisic acid and is the key event in alkaptonuria leading to the destructive consequences of the disease-A review
Lakshminarayan R. Ranganath et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2019)
Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuria
Juliette H. Hughes et al.
HUMAN MOLECULAR GENETICS (2019)
The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool
Anna M. Milan et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2017)
Metabolomics and Gene Expression Analysis Reveal Down-regulation of the Citric Acid (TCA) Cycle in Non-diabetic CKD Patients
Stein Hallan et al.
EBIOMEDICINE (2017)
Acute fatal metabolic complications in alkaptonuria
A. S. Davison et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2016)
Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment
Lakshminarayan R. Ranganath et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Intratumoral estrogen sulfotransferase induction contributes to the anti-breast cancer effects of the dithiocarbamate derivative TM208
Xi-wei Ji et al.
ACTA PHARMACOLOGICA SINICA (2015)
Untargeted UPLC-MS Profiling Pipeline to Expand Tissue Metabolome Coverage: Application to Cardiovascular Disease
Panagiotis A. Vorkas et al.
ANALYTICAL CHEMISTRY (2015)
Outcome of children with hereditary tyrosinaemia following newborn screening
P. J. McKiernan et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2015)
Renal and prostate stones composition in alkaptonuria: a case report
Fleur Wolff et al.
CLINICAL NEPHROLOGY (2015)
Oxidative stress and mechanisms of ochronosis in alkaptonuria
Daniela Braconi et al.
FREE RADICAL BIOLOGY AND MEDICINE (2015)
Metabolomics insights into chronic kidney disease and modulatory effect of rhubarb against tubulointerstitial fibrosis
Zhi-Hao Zhang et al.
SCIENTIFIC REPORTS (2015)
Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry
Andrew T. Hughes et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2015)
Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone
Andrew J. Preston et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Urine homogentisic acid and tyrosine: Simultaneous analysis by liquid chromatography tandem mass spectrometry
A. T. Hughes et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2014)
CFM-ID: a web server for annotation, spectrum prediction and metabolite identification from tandem mass spectra
Felicity Allen et al.
NUCLEIC ACIDS RESEARCH (2014)
Recent advances in management of alkaptonuria (invited review; best practice article)
Lakshminarayan R. Ranganath et al.
JOURNAL OF CLINICAL PATHOLOGY (2013)
Importance of UDP-Glucuronosyltransferase 1A1 Expression in Skin and Its Induction by UVB in Neonatal Hyperbilirubinemias
Kyohei Sumida et al.
MOLECULAR PHARMACOLOGY (2013)
Metabolite target analysis of human urine combined with pattern recognition techniques for the study of symptomatic gout
Yun Liu et al.
MOLECULAR BIOSYSTEMS (2012)
The role of calcified cartilage and subchondral bone in the initiation and progression of ochronotic arthropathy in alkaptonuria
A. M. Taylor et al.
ARTHRITIS AND RHEUMATISM (2011)
An update on molecular genetics of Alkaptonuria (AKU)
Andrea Zatkova
JOURNAL OF INHERITED METABOLIC DISEASE (2011)
A 3-year randomized therapeutic trial of nitisinone in alkaptonuria
Wendy J. Introne et al.
MOLECULAR GENETICS AND METABOLISM (2011)
Homeostatic Imbalance of Purine Catabolism in First-Episode Neuroleptic-Naive Patients with Schizophrenia
Jeffrey K. Yao et al.
PLOS ONE (2010)
Alkaptonuria - a review of surgical and autopsy pathology
T. R. Helliwell et al.
HISTOPATHOLOGY (2008)
Structure and redox properties of radicals derived from one-electron oxidised methylxanthines
Pedro M. P. Santos et al.
REDOX REPORT (2008)
Amino acid conjugation: contribution to the metabolism and toxicity of xenobiotic carboxylic acids
Kathleen M. Knights et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2007)
Automated assignment of high-resolution collisionally activated dissociation mass spectra using a systematic bond disconnection approach
AW Hill et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2005)
Natural history of alkaptonuria
C Phornphutkul et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Drug-metabolizing activity of human and rat liver, lung, kidney and intestine slices
R De Kanter et al.
XENOBIOTICA (2002)
Share Paper
